PDCD1 and Miyoshi myopathy: In clinical trials (KEYNOTE trials 183 and 185), the combination of immunomodulatory imide drugs (IMiDs) with PD-1 inhibition, pembrolizumab in combination with pomalidomide for relapsed or refractory MM, and pembrolizumab in combination with LEN for newly diagnosed MM patients resulted in decreased overall survival, which halted the trials (7, 8).